RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 101 filers reported holding RIGEL PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $88 | -60.5% | 10,573 | -93.0% | 0.00% | – |
Q1 2024 | $223 | -37.5% | 150,568 | -38.9% | 0.00% | – |
Q4 2023 | $357 | +693.3% | 246,503 | +491.9% | 0.00% | – |
Q3 2023 | $45 | -23.7% | 41,648 | -8.5% | 0.00% | – |
Q2 2023 | $59 | -55.0% | 45,496 | -53.9% | 0.00% | – |
Q1 2023 | $131 | +89.9% | 98,708 | +113.0% | 0.00% | – |
Q4 2022 | $69 | -99.2% | 46,336 | +533.3% | 0.00% | – |
Q3 2022 | $9,000 | -10.0% | 7,317 | -15.5% | 0.00% | – |
Q2 2022 | $10,000 | -93.1% | 8,661 | -82.2% | 0.00% | – |
Q1 2022 | $145,000 | -87.9% | 48,528 | -89.2% | 0.00% | – |
Q4 2021 | $1,194,000 | -8.0% | 449,970 | +26.0% | 0.00% | -100.0% |
Q3 2021 | $1,298,000 | +26.4% | 357,244 | +51.1% | 0.00% | – |
Q2 2021 | $1,027,000 | -29.2% | 236,452 | -44.2% | 0.00% | -100.0% |
Q1 2021 | $1,450,000 | +169.5% | 423,923 | +175.5% | 0.00% | – |
Q4 2020 | $538,000 | +22.0% | 153,887 | -16.5% | 0.00% | – |
Q3 2020 | $441,000 | -3.3% | 184,299 | -26.0% | 0.00% | – |
Q2 2020 | $456,000 | +40.3% | 248,959 | +19.4% | 0.00% | – |
Q1 2020 | $325,000 | -38.2% | 208,455 | -15.2% | 0.00% | – |
Q4 2019 | $526,000 | +34.2% | 245,711 | +17.3% | 0.00% | – |
Q3 2019 | $392,000 | -11.3% | 209,495 | +23.9% | 0.00% | – |
Q2 2019 | $442,000 | +59.0% | 169,116 | +56.4% | 0.00% | – |
Q1 2019 | $278,000 | +18.3% | 108,111 | +5.9% | 0.00% | – |
Q4 2018 | $235,000 | -73.1% | 102,099 | -62.4% | 0.00% | -100.0% |
Q3 2018 | $872,000 | -55.1% | 271,555 | -60.4% | 0.00% | 0.0% |
Q2 2018 | $1,940,000 | -41.0% | 685,105 | -26.2% | 0.00% | -66.7% |
Q1 2018 | $3,286,000 | +89.2% | 928,670 | +107.3% | 0.00% | +200.0% |
Q4 2017 | $1,737,000 | +258.9% | 447,991 | +135.2% | 0.00% | – |
Q3 2017 | $484,000 | -4.5% | 190,497 | +2.7% | 0.00% | – |
Q2 2017 | $507,000 | +378.3% | 185,469 | +478.8% | 0.00% | – |
Q1 2017 | $106,000 | -20.3% | 32,043 | -43.0% | 0.00% | – |
Q4 2016 | $133,000 | -25.7% | 56,207 | +14.1% | 0.00% | – |
Q3 2016 | $179,000 | -7.3% | 49,269 | -43.1% | 0.00% | – |
Q2 2016 | $193,000 | +101.0% | 86,651 | +80.6% | 0.00% | – |
Q1 2016 | $96,000 | +772.7% | 47,968 | +1259.3% | 0.00% | – |
Q4 2015 | $11,000 | +450.0% | 3,529 | +185.3% | 0.00% | – |
Q3 2015 | $2,000 | -97.7% | 1,237 | -95.8% | 0.00% | – |
Q2 2015 | $88,000 | +158.8% | 29,679 | +157.9% | 0.00% | – |
Q1 2015 | $34,000 | -20.9% | 11,507 | -46.9% | 0.00% | – |
Q4 2014 | $43,000 | -17.3% | 21,655 | -58.7% | 0.00% | – |
Q3 2014 | $52,000 | -63.9% | 52,430 | +8.0% | 0.00% | – |
Q2 2014 | $144,000 | -40.2% | 48,539 | -39.8% | 0.00% | – |
Q1 2014 | $241,000 | +213.0% | 80,641 | +105.5% | 0.00% | – |
Q4 2013 | $77,000 | -54.2% | 39,244 | -30.0% | 0.00% | – |
Q3 2013 | $168,000 | -40.4% | 56,059 | -33.5% | 0.00% | – |
Q2 2013 | $282,000 | – | 84,280 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |